Peptides / Brain and mood

Undefined product

Cortexin (cortical polypeptide complex)

Approved in Russia

Cortexin is a mix of peptides from animal brain cortex, approved in Russia as a prescription medicine. Studies in people tested it on memory and thinking, brain protection and mood, and animal studies looked at brain injury. PepBank shows 140 results on Cortexin from 46 studies in people, and 112 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Cortexin, Korteksin, Кортексин

Evidence level: Large trials in people140 of 252 results come from studies in people, including randomized trials.

Results in people

140

56% of 252 results

Results in animals

36% of 252 results

Results in lab cells

8% of 252 results

From computer models

0% of 252 results

Overview

Cortexin (cortical polypeptide complex) at a glance

What it is	Undefined product
Approval	Approved in Russia only (registered as Cortexin / Кортексин)
In sport	Status unknown
Studies	97 studies with results. 77 of them gave Cortexin, with 252 results. 140 in people91 in animals21 in lab cells
Best study in people	Randomized controlled trial with 490 people (2025)
Clinical trials	None registered
Community use	Russian labeled adjunct use for neurological disorders

The science

What is Cortexin?

A Russian prescription product containing an animal cerebral cortex polypeptide complex.

252

Study results in PepBank

Cortexin (cortical polypeptide complex) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Structure

Cortexin (cortical polypeptide complex) is a undefined product, with no ring, no changed amino acids.

Development

GEROPHARM. Highest phase: past the trial stage (see status).

See charge, composition and 3D structure on the Scientific page

The evidence

What Cortexin studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people140 of 252 results come from studies in people, including randomized trials.

Memory and thinking

48 results · 43 in people · 5 animal

In stroke patients, MMSE score changes did not differ significantly between initial intravenous Cortexin and intramuscular Cortexin. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2025

Top results

In stroke patients, MMSE score changes did not differ significantly between initial intravenous Cortexin and intramuscular Cortexin. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2025)
In patients with diabetes complications, cognitive symptoms decreased more with added Cortexin than with comprehensive treatment alone. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2026)
In patients recovering from ischemic stroke, Cortexin had less cognitive improvement than Cellex. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2020)

Brain and nerves

99 results · 36 in people · 54 animal · 9 lab

In chronic cerebral ischemia, Cortexin effects on neurological disorders, asthenia and sleep disturbance depended on dose. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2018

Top results

In chronic cerebral ischemia, Cortexin effects on neurological disorders, asthenia and sleep disturbance depended on dose. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2018)
In patients with epilepsy, seizures became less frequent during cortexin treatment with standard therapy. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2014)
In children with sluggish cognitive tempo, frontal and central brain alpha-wave power decreased after Cortexin treatment compared with pretreatment. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2026)

Daily life and fitness

16 results · 12 in people · 4 animal

In stroke patients, the share with a favorable disability score at day 90 was 93.64% with initial intravenous Cortexin and 86.50% with intramuscular Cortexin. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2025

Top results

In stroke patients, the share with a favorable disability score at day 90 was 93.64% with initial intravenous Cortexin and 86.50% with intramuscular Cortexin. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2025)
After ischemic stroke, repeated cortexin improved quality of life more than a single course. (Klinicheskaia meditsina, 2016)
In patients with depression, added Cortexin improved quality of life more than antidepressant treatment alone. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2026)

Mood, stress and behavior

14 results · 10 in people · 4 animal

In chronic cerebral ischemia, Cortexin's antidepressant effect after repeated courses was insignificant. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2018

Top results

In chronic cerebral ischemia, Cortexin's antidepressant effect after repeated courses was insignificant. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2018)
In patients with diabetes complications, anxiety scores decreased with added Cortexin, with minimal changes in controls. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2026)
In patients recovering from ischemic stroke, depression improvement showed a nonsignificant trend favoring Cellex over Cortexin. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2020)

Immune system and inflammation

17 results · 6 in people · 10 animal · 1 lab

In infants with moderate perinatal brain damage, added Cortexin reduced IL-Iß, while standard therapy alone did not correct cytokine levels. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2025

Top results

In infants with moderate perinatal brain damage, added Cortexin reduced IL-Iß, while standard therapy alone did not correct cytokine levels. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2025)
In mice immunized with SRBC, cortexin increased production of cells that make IgM antibodies. (Zhurnal mikrobiologii, epidemiologii i immunobiologii, 1980)
In rats, Cortexin reduced brain TNF alpha content versus control. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2026)

Overall treatment results

5 results · 5 in people

In patients with diabetes complications, 83.3% of the Cortexin group showed good or very good improvement. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2026

Top results

In patients with diabetes complications, 83.3% of the Cortexin group showed good or very good improvement. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2026)
In healthy volunteers, Cortexin showed adaptation and performance protection only under low-pressure, low-oxygen conditions. (Eksperimental'naia i klinicheskaia farmakologiia, 2007)
In patients with brain ischemia, focal neurological symptoms decreased or disappeared during cortexin treatment. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2014)

All 97 Cortexin studies by area Open the Scientific page

Key Cortexin studies

Studies in people come first, then studies in animals and in the lab.

People
[Therapeutic equivalence of intravenous and intramuscular dosage forms of Cortexin in ischemic strokes]
Fedin et al. 2025 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 490 people · cited by 0
4 results
People
[Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study)]
Fedin et al. 2018 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 189 people · cited by 16
6 results
People
[Cortexin in the comprehensive treatment of neurological complications of type 2 diabetes mellitus. (Results of the DIACORT multicenter randomized clinical trial)]
2026 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 110 people · cited by 0
11 results
People
[Efficacy of reflexology in the combination with neuroprotective treatment in hemiparetic form of children cerebral palsy]
Ukhanova et al. 2012 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 60 people · cited by 0
3 results
People
[Proinflammatory cytokines - as a marker of the effectiveness of neuroprotection in children with perinatal nervous system damage]
Degtyareva et al. 2025 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 58 people · cited by 0
6 results

All 97 Cortexin (cortical polypeptide complex) studies

Cortexin clinical trials

ClinicalTrials.gov lists no trial of Cortexin. A trial under another name may exist.

Status and safety

Is Cortexin approved?

FDA

United States

Status unknown

Status unknown.

EMA

European Union

Status unknown

Status unknown.

WADA

Sport

Not recorded

Status unknown.

Yes. Approved in Russia only (registered as Cortexin / Кортексин). Status unknown.

Laws and labels change, so check the regulator for the current status.

Cortexin side effects and safety

PepBank has 18 safety results from studies of Cortexin. 14 of them come from studies in people.

Safety results from studies (18)

In stroke patients, adverse event counts did not differ significantly between initial intravenous Cortexin and intramuscular Cortexin. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2025)
In patients with diabetes complications, adverse events occurred in both groups, and none were related to therapy. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2026)
In patients with chronic cerebral ischemia, the study reported that cortexin was safe and well tolerated, with no event counts given. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2018)
In patients with alcohol disorders or polyneuropathy, cortexin was well tolerated without observed side effects. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010)
In children with cognitive dysfunction, the study reported good Cortexin tolerability without event counts. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2018)
In patients with depression, added Cortexin reduced adverse events more than antidepressant treatment alone. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2026)
No adverse events occurred in patients who received Cortexin for post-Covid cognitive impairment. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2024)
In patients with dyscirculatory encephalopathy, cortexin was well tolerated and no side effects were reported. (Klinicheskaia meditsina, 1999)
After ischemic stroke, no side effects of cortexin treatment were observed. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2009)
In patients with acute ischemic stroke, the study reported cortexin safety without specific event data. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2008)
In patients with ischemic stroke, the study reported high safety for cortexin but gave no event details. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2014)
In children with delayed speech development, cortexin monotherapy had good tolerance. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2021)
In patients with ischemic stroke, the abstract reported no side effects with Cortexin. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2006)
No patient had adverse interactions between Cortexin and their other drugs during observation. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2024)
In rats without injury, cortexin disturbed autonomic balance. (Zhurnal evoliutsionnoi biokhimii i fiziologii, 2016)
In rats without injury, cortexin disturbed heart rhythm. (Zhurnal evoliutsionnoi biokhimii i fiziologii, 2016)
In rats without injury, cortexin disturbed breathing rhythm less than autonomic balance and heart rhythm. (Zhurnal evoliutsionnoi biokhimii i fiziologii, 2016)
In cells, Cortexin had toxic effects on T-lymphocytes at certain concentrations. (Eksperimental'naia i klinicheskaia farmakologiia, 2009)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
10 mg twice daily	Human	human	intravenous or intramuscular in the first course, intramuscular in the second course	two courses of 10 days each	Randomized trial in people · n = 490	Fedin 2025
10 mg or 20 mg	Human	human	intramuscular	10-day course repeated after 6 months	Randomized trial in people · n = 189	Fedin 2018
10 mg	Human	human	intramuscular	ten doses	Randomized trial in people · n = 110	2026
10 mg	Human	human	intramuscular	Two courses, 10 injections per course	Randomized trial in people · n = 60	Ukhanova 2012
10 mg daily	Human	human	intramuscular	10 days	Randomized trial in people · n = 40	Khabirov 2020
10 mg/d	Human	human	intramuscular	10 days	Randomized trial in people	Solov'ev 2010
10 mg/day	Human	human	Not reported	10 days	Trial in people without random groups · n = 500	Mashin 2014
10 mg three times a day	Human	human	intramuscular	Not reported	Trial in people without random groups · n = 272	Aliferova 2014
10 mg once daily	Human	human	intramuscular	10 days	Trial in people without random groups · n = 98	Schastnyy 2026
10 mg once a day	Human	human	intramuscular	10 days per course, repeated at 3, 6, 9 months during the year	Trial in people without random groups · n = 80	Evzel'man 2013
10 mg	Human	human	intramuscular	Two courses of 10 injections	Trial in people without random groups · n = 74	Ukhanova 2012
10 mg daily	Human	human	intramuscular	10 days	Trial in people without random groups · n = 68	Nurguzhaev 2009
10 mg daily	Human	human	intramuscular	Three 10-day courses during 12 months	Trial in people without random groups · n = 64	Belskaya 2014
30 mg daily (10+10+10)	Human	human	Not reported	Two 10-day courses separated by 10 days	Trial in people without random groups · n = 62	Belova 2018
20 mg daily	Human	human	intramuscular	10 days	Trial in people without random groups · n = 62	Skoromets 2008
20 mg per day	Human	human	intramuscular	10 days	Trial in people without random groups · n = 60	Mashin 2019
10 mg	Human	human	intramuscular	20 days	Trial in people without random groups · n = 52	Melnik 2024
10 mg	Human	human	intramuscular	15 days	Trial in people without random groups · n = 46	Gafurov 2010
10 mg every other day	Human	human	intramuscular	10 injections	Trial in people without random groups · n = 40	Chutko 2026
20 mg (10+10)	Human	human	intramuscular	Not reported	Trial in people without random groups	Belova 2016
20 mg (10+10)	Human	human	intramuscular	Two 10-day courses with a 10-day interval	Trial in people without random groups	Belova 2016
10 mg twice daily	Human	human	intramuscular	Not reported	Trial in people without random groups	Belova 2016
10 mg	Human	human	intramuscular	10 days	Observational study · n = 50	Putilina 2024
1.7 mg/kg	Animal	rat	intraperitoneal	10 consecutive days	Study in live animals	Zhang 2019
0.15 mg/kg	Animal	rat	intraperitoneal	Not reported	Study in live animals · n = 16	Ponomarev 2017
1 mg/kg	Animal	rat	intraperitoneal	single injection	Study in live animals · n = 10	Shchulkin 2026
1 or 3 mg/kg/day	Animal	rat	Not reported	10 days	Study in live animals	Kurkin 2021
1 and 3 mg/kg	Animal	rat	Not reported	two 10-day courses with a 10-day break	Study in live animals	Tyurenkov 2020
3 mg/kg/day	Animal	rat	Not reported	two ten-day courses separated by 10 days	Study in live animals	Kurkin 2021
2 mg/day	Animal	rat	intraperitoneal	7 days	Study in live animals	Eroğlu 2018
3 mg/day	Animal	rabbit	intramuscular	10 days	Study in live animals	Tunçcan 2016
0.015, 0.15 and 1.0 mg/kg	Animal	rat	intraperitoneal in solution or intranasal with nanoparticles	long-term preliminary administration	Study in live animals	Aniol 2011
1, 10, and 100 microg	Animal	rat	into brain ventricles	Not reported	Study in live animals	Shabanov 2007
1 or 2 mg/kg	Animal	Wistar albino rats	Not reported	Not reported	Study in live animals	Guven 2026
2 mg/kg	Animal	Wistar albino rats	Not reported	Not reported	Study in live animals	Guven 2026
1 mg/kg	Animal	rat	intraperitoneal	10 days	Study in live animals	Kuznetsov 2016
Intraventricular: 1 mg to 10 mg and 100 mg. Intraperitoneal: 1 mg/kg.	Animal	rat	intraventricular and intraperitoneal	Not reported	Study in live animals	Shabanov 2007
1 mg to 10 mg and 100 mg	Animal	rat	intraventricular	Not reported	Study in live animals	Shabanov 2007
1 mg/kg	Animal	rat	intraperitoneal	Not reported	Study in live animals	Shabanov 2007
1 mg/kg	Animal	rat	intraperitoneal	Not reported	Study in live animals	Shabanov 2007

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

Medi.ru reproduces Russian prescribing instructions for Cortexin. The regimen describes labeled use, not unapproved community practice or proof of clinical benefit.

Reported routines and cautions

What people use it for

Russian labeled adjunct use for neurological disordersS1

Reported regimens

Regimens that community sources report for Cortexin. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
General adult neurological adjunct use in reproduced Russian instructions, excluding the separate hemispheric ischemic stroke scheduleOfficial label dosing of an approved product	intramuscular injection	10 mg per dose	once daily	10 days	Medi.ru reproduces Russian approved instructions and includes pharmacy referral links. This is one reproduced label, not independent community agreement. This review did not retrieve a direct state register document.	S1

Cautions

The reproduced label contraindicates use in pregnancy and describes individual intolerance. It does not establish FDA or EMA approval.S1

Status notes

The manufacturer and reproduced instructions report Russian prescription registration Р N003862/02. S3 is the register homepage only. This review did not retrieve a product record or confirm current registration status.S1S3

Community sources

S1Russian Cortexin prescribing instructionsmedi.rucarries seller links, not linked
S3Russian state medicine register (opens in a new tab)grls.rosminzdrav.ru

plus 1 seller page (not linked)

Gaps

This record contains no independently sourced community practice. Medi.ru reproduces a Russian label and includes pharmacy referral links. The manufacturer corroborates prescription status and registration number. The register homepage does not establish current product registration. These sources do not establish FDA or EMA approval, clinical benefit, or regimen safety.

Questions and more

Ask a question about Cortexin

The answer links to every study it uses.

What does the evidence say about Cortexin?Is Cortexin tested in people?Compare with Cerebrolysin Compare with Delta sleep-inducing peptide (DSIP)

Sources

Database: PepBank data for Cortexin (data version 308560)
Regulator: WADA status record
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about Cortexin

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Cortexin (cortical polypeptide complex)

Approved in Russia

Also known as Cortexin, Korteksin, Кортексин

What it is

Undefined product

Approval

Approved in Russia only (registered as Cortexin / Кортексин)

In sport

Status unknown

Studies

97 studies with results. 77 of them gave Cortexin, with 252 results.
140 in people91 in animals21 in lab cells

Best study in people

Randomized controlled trial with 490 people (2025)

Clinical trials

None registered

Community use

Russian labeled adjunct use for neurological disorders

Dose as reported

Class

Species

Route

Duration

Design

Source

10 mg twice daily

Human

human

intravenous or intramuscular in the first course, intramuscular in the second course

two courses of 10 days each

Randomized trial in people · n = 490

Fedin 2025

10 mg or 20 mg

Human

human

intramuscular

10-day course repeated after 6 months

Randomized trial in people · n = 189

Fedin 2018

10 mg

Human

human

intramuscular

ten doses

Randomized trial in people · n = 110

2026

10 mg

Human

human

intramuscular

Two courses, 10 injections per course

Randomized trial in people · n = 60

Ukhanova 2012

10 mg daily

Human

human

intramuscular

10 days

Randomized trial in people · n = 40

Khabirov 2020

10 mg/d

Human

human

intramuscular

10 days

Randomized trial in people

Solov'ev 2010

10 mg/day

Human

human

Not reported

10 days

Trial in people without random groups · n = 500

Mashin 2014

10 mg three times a day

Human

human

intramuscular

Not reported

Trial in people without random groups · n = 272

Aliferova 2014

10 mg once daily

Human

human

intramuscular

10 days

Trial in people without random groups · n = 98

Schastnyy 2026

10 mg once a day

Human

human

intramuscular

10 days per course, repeated at 3, 6, 9 months during the year

Trial in people without random groups · n = 80

Evzel'man 2013

10 mg

Human

human

intramuscular

Two courses of 10 injections

Trial in people without random groups · n = 74

Ukhanova 2012

10 mg daily

Human

human

intramuscular

10 days

Trial in people without random groups · n = 68

Nurguzhaev 2009

10 mg daily

Human

human

intramuscular

Three 10-day courses during 12 months

Trial in people without random groups · n = 64

Belskaya 2014

30 mg daily (10+10+10)

Human

human

Not reported

Two 10-day courses separated by 10 days

Trial in people without random groups · n = 62

Belova 2018

20 mg daily

Human

human

intramuscular

10 days

Trial in people without random groups · n = 62

Skoromets 2008

20 mg per day

Human

human

intramuscular

10 days

Trial in people without random groups · n = 60

Mashin 2019

10 mg

Human

human

intramuscular

20 days

Trial in people without random groups · n = 52

Melnik 2024

10 mg

Human

human

intramuscular

15 days

Trial in people without random groups · n = 46

Gafurov 2010

10 mg every other day

Human

human

intramuscular

10 injections

Trial in people without random groups · n = 40

Chutko 2026

20 mg (10+10)

Human

human

intramuscular

Not reported

Trial in people without random groups

Belova 2016

20 mg (10+10)

Human

human

intramuscular

Two 10-day courses with a 10-day interval

Trial in people without random groups

Belova 2016

10 mg twice daily

Human

human

intramuscular

Not reported

Trial in people without random groups

Belova 2016

10 mg

Human

human

intramuscular

10 days

Observational study · n = 50

Putilina 2024

1.7 mg/kg

Animal

rat

intraperitoneal

10 consecutive days

Study in live animals

Zhang 2019

0.15 mg/kg

Animal

rat

intraperitoneal

Not reported

Study in live animals · n = 16

Ponomarev 2017

1 mg/kg

Animal

rat

intraperitoneal

single injection

Study in live animals · n = 10

Shchulkin 2026

1 or 3 mg/kg/day

Animal

rat

Not reported

10 days

Study in live animals

Kurkin 2021

1 and 3 mg/kg

Animal

rat

Not reported

two 10-day courses with a 10-day break

Study in live animals

Tyurenkov 2020

3 mg/kg/day

Animal

rat

Not reported

two ten-day courses separated by 10 days

Study in live animals

Kurkin 2021

2 mg/day

Animal

rat

intraperitoneal

7 days

Study in live animals

Eroğlu 2018

3 mg/day

Animal

rabbit

intramuscular

10 days

Study in live animals

Tunçcan 2016

0.015, 0.15 and 1.0 mg/kg

Animal

rat

intraperitoneal in solution or intranasal with nanoparticles

long-term preliminary administration

Study in live animals

Aniol 2011

1, 10, and 100 microg

Animal

rat

into brain ventricles

Not reported

Study in live animals

Shabanov 2007

1 or 2 mg/kg

Animal

Wistar albino rats

Not reported

Study in live animals

Guven 2026

2 mg/kg

Animal

Wistar albino rats

Not reported

Study in live animals

Guven 2026

1 mg/kg

Animal

rat

intraperitoneal

10 days

Study in live animals

Kuznetsov 2016

Intraventricular: 1 mg to 10 mg and 100 mg. Intraperitoneal: 1 mg/kg.

Animal

rat

intraventricular and intraperitoneal

Not reported

Study in live animals

Shabanov 2007

1 mg to 10 mg and 100 mg

Animal

rat

intraventricular

Not reported

Study in live animals

Shabanov 2007

1 mg/kg

Animal

rat

intraperitoneal

Not reported

Study in live animals

Shabanov 2007

1 mg/kg

Animal

rat

intraperitoneal

Not reported

Study in live animals

Shabanov 2007

Context

Route

Amount

How often

How long

Agreement

Sources

General adult neurological adjunct use in reproduced Russian instructions, excluding the separate hemispheric ischemic stroke scheduleOfficial label dosing of an approved product

intramuscular injection

10 mg per dose

once daily

10 days

Medi.ru reproduces Russian approved instructions and includes pharmacy referral links. This is one reproduced label, not independent community agreement. This review did not retrieve a direct state register document.

Cortexin (cortical polypeptide complex)

Cortexin (cortical polypeptide complex) at a glance

What is Cortexin?

Cortexin (cortical polypeptide complex) structure and chemistry

What Cortexin studies show

Memory and thinking

Brain and nerves

Daily life and fitness

Mood, stress and behavior

Immune system and inflammation

Overall treatment results

Key Cortexin studies

Cortexin clinical trials

Is Cortexin approved?

Cortexin side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about Cortexin

Related peptides

Sources

Cortexin (cortical polypeptide complex)

Cortexin (cortical polypeptide complex) at a glance

What is Cortexin?

Cortexin (cortical polypeptide complex) structure and chemistry

What Cortexin studies show

Memory and thinking

Brain and nerves

Daily life and fitness

Mood, stress and behavior

Immune system and inflammation

Overall treatment results

Key Cortexin studies

Cortexin clinical trials

Is Cortexin approved?

Cortexin side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about Cortexin

Related peptides

Sources